Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
ALMS - Alumis Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$39.33
DETAILS
HIGH:
$51.00
LOW:
$25.00
MEDIAN:
$39.00
CONSENSUS:
$39.33
UPSIDE:
78.61%
Stock News
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) –
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, have been accepted for a late-breaking oral presentation, and that a new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib has been accepted as an e-poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31, 2026, in Denver, Colorado.
Alumis to Present at the Leerink Partners Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET.
AXQ Capital LP Invests $78,000 in Alumis Inc. $ALMS
AXQ Capital LP bought a new stake in Alumis Inc. (NASDAQ: ALMS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,452 shares of the company's stock, valued at approximately $78,000. Several other hedge funds and other institutional investors
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS
Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 36.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,002 shares of the company's stock after selling 140,000 shares during the quarter. Credit
Alumis to Participate in Upcoming February Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January
Alumis Inc. (NASDAQ: ALMS - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 8,672,088 shares, a growth of 93.1% from the December 31st total of 4,492,125 shares. Based on an average daily trading volume, of 10,417,053 shares,
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million
Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of Jan. 9, 2026. This purchase represented 46.49% of Srinivas Akkaraju's previously reported indirect holdings.
David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.
Alumis (NASDAQ:ALMS) Trading 6.6% Higher Following Insider Buying Activity
Alumis Inc. (NASDAQ: ALMS - Get Free Report) traded up 6.6% during mid-day trading on Wednesday following insider buying activity. The stock traded as high as $23.94 and last traded at $23.5690. 1,274,140 shares were traded during trading, a decline of 89% from the average session volume of 11,453,423 shares. The stock had previously closed at
Alumis (NASDAQ:ALMS) Major Shareholder Foresite Labs, Llc Purchases 411,764 Shares
Alumis Inc. (NASDAQ: ALMS - Get Free Report) major shareholder Foresite Labs, Llc purchased 411,764 shares of Alumis stock in a transaction dated Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the transaction, the insider directly owned 5,702,536 shares in the company,
Alumis (NASDAQ:ALMS) Director Srinivas Akkaraju Acquires 588,235 Shares of Stock
Alumis Inc. (NASDAQ: ALMS - Get Free Report) Director Srinivas Akkaraju acquired 588,235 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director owned 1,853,488 shares
Price Targets
Alumis price target raised to $40 from $38 at Chardan
$40.00
(was $21.09)
Chardan Capital
Alumis price target raised to $39 from $38 at Morgan Stanley
$39.00
(was $23.82)
Terence Flynn
·
Morgan Stanley
Alumis price target raised to $51 from $49 at Wells Fargo
$51.00
(was $24.63)
Wells Fargo
Alumis price target raised to $34 from $32 at Guggenheim
$34.00
(was $24.63)
Yatin Suneja
·
Guggenheim
Alumis downgraded to Neutral from Buy at H.C. Wainwright
$25.00
(was $24.63)
Mitchell Kapoor
·
H.C. Wainwright
Raymond James Starts Alumis Inc (ALMS) at Strong Buy
$46.00
(was $28.10)
Christopher Raymond
·
Raymond James
Alumis initiated with a Buy at Chardan
$37.00
(was $26.06)
Chardan Capital
Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy
$37.00
(was $26.06)
Janani Sundararajan
·
Loop Capital Markets
Alumis price target raised to $40 from $20 at H.C. Wainwright
$40.00
(was $18.18)
H.C. Wainwright
Alumis price target raised to $33 from $22 at Morgan Stanley
$33.00
(was $16.23)
Morgan Stanley
Alumis price target raised to $32 from $18 at Guggenheim
$32.00
(was $16.23)
Yatin Suneja
·
Guggenheim
Alumis price target raised to $50 from $25 at Oppenheimer
$50.00
(was $16.23)
Jeff Jones
·
Oppenheimer
Alumis price target raised to $32 from $20 at Leerink
$32.00
(was $16.23)
Leerink Partners
Alumis price target raised to $39 from $17 at Wells Fargo
$39.00
(was $16.97)
Derek Archila
·
Wells Fargo
Alumis price target raised to $20 from $14 at H.C. Wainwright
$20.00
(was $11.00)
Mitchell Kapoor
·
H.C. Wainwright
Baird Starts Alumis Inc (ALMS) at Outperform
$25.00
(was $11.23)
Brian Skorney
·
Robert W. Baird
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
$30.00
(was $11.03)
Mitchell Kapoor
·
H.C. Wainwright
Alumis initiated with an Overweight at Cantor Fitzgerald
$13.00
(was $13.00)
Eric Schmidt
·
Cantor Fitzgerald